Loading, Please Wait...
SAN FRANCISCO, May 21, 2019 (GLOBE NEWSWIRE) -- Vineti Inc., the leading software platform of record for personalized therapeutics, today announced the opening of new regional headquarters in Bethesda, Maryland, to support the expanding cell and gene therapy corridor on the East Coast.
“Vineti is growing rapidly alongside the thriving ecosystem of personalized therapeutics,” said Vineti CEO Amy DuRoss. “While we’ve always enjoyed supporting our East Coast clients, we’re now very excited to establish ourselves directly in the community, and further solidify our business leadership and connections in the personalized therapeutic ecosystem.”
More than 1,000 cell and gene therapy clinical trials are currently active globally, with a large concentration of personalized therapy development and manufacturing located in states such as Maryland, Massachusetts, New Jersey and Pennsylvania. Vineti’s Personalized Therapy Management platform is already enabling several therapeutic pipelines in the region. Vineti’s platform is the first commercially available, cloud-based software platform to safely and efficiently move patient-based personalized therapies through clinical development and into mainstream medicine at scale.
"We're excited to see the continued growth of the advanced therapy sector in this region," said Morrie Ruffin, Managing Partner of Adjuvant Partners, and Co-Founder and Senior Advisor to the Washington D.C.-based Alliance for Regenerative Medicine.
Ruffin noted that a range of industry leaders, including Kite Pharma, Lonza, Autolus Therapeutics, Paragon Bioservices,Lentigen/Miltenyi, and Orgenesis/Masthercell have established facilities in the Washington D.C region. "Alongside other recent announcements of new cell and gene therapy investment in the metro D.C area, this ongoing growth demonstrates our sector's overall forward momentum," Ruffin said.
Vineti’s Bethesda office will formally open its doors on May 21, 2019. This news follows other recent announcements such as Vineti’s alliance with CareMetx, a technology-enabled hub and patient services provider.
About Vineti, Inc.
Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti software solution aligns and orchestrates the cell and gene therapy process and improve product performance overall, and supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The platform can also be harnessed for drug products requiring companion diagnostics or REMS programs. Vineti is expanding rapidly, and its platform will be in use in hundreds of leading medical centers world-wide in 2019, on behalf of multiple biopharmaceutical partners. The company has offices in San Francisco, California; Bethesda, Maryland; and Yerevan, Armenia. For more information, please visit www.vineti.com.
Director, PR and Scientific Communications